🇺🇸 FDA
Patent

US 9867785

Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells

granted A61KA61K31/704A61K47/6879

Quick answer

US patent 9867785 (Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells) held by EnGeneIC Molecular Delivery Pty Ltd expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
EnGeneIC Molecular Delivery Pty Ltd
Grant date
Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/704, A61K47/6879, A61K47/6901, A61K9/5068